Exelixis Non Current Liabilities Other from 2010 to 2025

EXEL Stock  USD 32.93  0.03  0.09%   
Exelixis Non Current Liabilities Other yearly trend continues to be quite stable with very little volatility. Non Current Liabilities Other may rise above about 113.8 M this year. From the period between 2010 and 2025, Exelixis, Non Current Liabilities Other regression line of its data series had standard deviation of  67,821,057 and standard deviation of  67,821,057. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2011-03-31
Previous Quarter
109.7 M
Current Value
96.1 M
Quarterly Volatility
64.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Exelixis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exelixis' main balance sheet or income statement drivers, such as Interest Expense of 64.9 M, Total Revenue of 2.2 B or Gross Profit of 2.1 B, as well as many indicators such as Price To Sales Ratio of 4.38, Dividend Yield of 0.0 or PTB Ratio of 4.24. Exelixis financial statements analysis is a perfect complement when working with Exelixis Valuation or Volatility modules.
  
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Latest Exelixis' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Exelixis over the last few years. It is Exelixis' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exelixis' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Exelixis Non Current Liabilities Other Regression Statistics

Arithmetic Mean49,522,192
Geometric Mean18,454,451
Coefficient Of Variation136.95
Mean Deviation48,555,366
Median17,339,000
Standard Deviation67,821,057
Sample Variance4599.7T
Range258.2M
R-Value0.62
Mean Square Error3005.8T
R-Squared0.39
Significance0.01
Slope8,897,181
Total Sum of Squares68995.4T

Exelixis Non Current Liabilities Other History

2025113.8 M
2024108.4 M
202394.2 M
2022258.7 M
2021M
202053.6 M
201957 M

About Exelixis Financial Statements

Exelixis investors utilize fundamental indicators, such as Non Current Liabilities Other, to predict how Exelixis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Other108.4 M113.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
121.699
Earnings Share
1.55
Revenue Per Share
7.032
Quarterly Revenue Growth
0.143
Return On Assets
0.1281
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.